记者了解到，目前海正药业富阳基地已成功承接硕腾、柯迪华等国际巨头的CMO订单，并持续推进依 维莫司等新产品注册，未来有望成为国际医药产业链的重要一环。 在医药制剂业务方面，海正药业率先在国内实现注射剂出口美国市场，保持国际领先GMP水平，将国 际标准与中国制药实际需求深度结合。海正药业医药制剂业务主要由全资子公司瀚晖制药负责，瀚晖制 药独创"三严四化"质量管理模式，引进原研药技术并实现本地化生产，目前已成功完成玫满、多达一、 特治星、美卓乐、甲强龙五款境外原研产品的技术转移，填补国内原研产品地产化转移技术空白。如 今，瀚晖工厂是国家短缺药和小品种生产基地，解决了多个短缺药品种的临床供应保障问题。 动物药板块是海正药业重点扶持打造的具有高潜力的业务板块，海正药业主要通过旗下海正动保布局动 物健康领域。据悉，海正动保依托云南生物疫苗基地与富阳化药基地，搭建起覆盖猪、反刍、宠物三大 类产品群的产品矩阵，海正动保拥有15个国家二类新兽药证书、20个在研产品、60余个批准文号、10余 个单品销售超千万的产品，且多款产品创下行业纪录，如海乐妙成为首个销售额破亿的国产驱虫药、海 乐旺成功登陆越南市场、推出品牌首款国产猫三联 ...

Group 1 - The article highlights the global concern over hypertension, with approximately 1.3 billion people affected, and emphasizes the severe challenge in China where only 16% of the 250 million hypertensive patients achieve treatment targets [1] - The combination of hypertension and dyslipidemia significantly increases the risk of cardiovascular diseases, making effective management of both conditions a key focus in the industry [1] - The introduction of a compound drug named "Duodayi" represents a new paradigm in the combined treatment of hypertension and dyslipidemia, addressing the shortcomings of previous treatment methods [1][3] Group 2 - The compound formulation combines amlodipine and atorvastatin, which are well-known and widely used medications for hypertension and dyslipidemia, respectively [2] - Pfizer's early patent application for the combination in 1998 laid the groundwork for the development of the world's first dual-action compound drug, which received FDA approval in 2004 and has since been recognized globally [2][6] - The drug "Caduet" (Duodayi) has been approved in over 70 countries and has become a significant player in the cardiovascular medication market [2][6] Group 3 - The single-tablet formulation improves patient adherence to treatment, with a reported 26% increase in the proportion of patients maintaining treatment over 12 months compared to taking two separate medications [4] - The dual-action drug has shown a significant improvement in achieving both blood pressure and lipid level targets compared to single medications or free combinations [6] Group 4 - In July 2021, Haizheng Pharmaceutical began local production of Duodayi, maintaining original drug quality while reducing adverse reactions and treatment costs by 25% compared to single medications [7] - The drug is available in multiple dosages, allowing for tailored treatment plans based on individual patient needs, enhancing treatment efficiency [7] Group 5 - Haizheng Pharmaceutical emphasizes quality control and has implemented a comprehensive management system to ensure high standards in production, achieving FDA certification [8] - The company has adopted a digital transformation strategy, integrating modern information technology with advanced manufacturing processes to enhance the entire lifecycle of drug production [8][9] Group 6 - Duodayi is positioned as a solution for chronic disease management, simplifying medication regimens for patients and showcasing the potential of local pharmaceutical innovation [9] - The success of Duodayi reflects the growth and evolution of the Chinese pharmaceutical industry, demonstrating that local production can match or exceed the quality of original formulations [9]